A first indication in support of our hypothesis came from the analysis of the GSE 19234 dataset of metastatic melanoma patients: similarly to what has been reported for PGC1alpha levels [3], we found that metastatic melanoma patients with high TRPM1/EDEM1 ratio are characterized by lower overall survival compared to those with low TRPM1/EDEM1 ratio (Figure 9a and Supplementary Figure 25-27; see also ref [49]). The gene discussed is TRPM1; the disease is metastatic melanoma.